The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
Authors: By Jon Cohen, Kai KupferschmidtOct. 28, 2020 , 7:05 PM October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 […]